Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group

Equities research analysts at Maxim Group initiated coverage on shares of Mainz Biomed (NASDAQ:MYNZ) in a report issued on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $14.00 price target on the stock. Maxim Group’s price target suggests a potential upside of 131.79% from the stock’s current price.

Separately, HC Wainwright cut shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a research note on Monday, November 25th.

Mainz Biomed Price Performance

Shares of Mainz Biomed stock opened at $6.04 on Friday. The stock has a market cap of $12.08 million, a price-to-earnings ratio of -0.09 and a beta of 0.32. The firm’s 50-day moving average is $5.32 and its 200 day moving average is $9.32. Mainz Biomed has a 1 year low of $3.65 and a 1 year high of $45.60.

Institutional Investors Weigh In On Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC bought a new position in Mainz Biomed (NASDAQ:MYNZ) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned approximately 0.92% of Mainz Biomed at the end of the most recent quarter.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.